Sarepta Therapeutics, Inc. (SRPT) News
Filter SRPT News Items
SRPT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SRPT News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SRPT News From Around the Web
Below are the latest news stories about SAREPTA THERAPEUTICS INC that investors may wish to consider to help them evaluate SRPT as an investment opportunity.
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., January 06, 2025--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. on Monday, Jan. 13, 2025 at 12:00 p.m. E.T. / 9:00 a.m. P.T. Following the presentation there will be a Q&A session starting at 12:20 p.m. E.T. / 9:20 a.m. P.T. |
SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?The upside in Sarepta's share price can be attributed to the encouraging sales performance of its DMD gene therapy, which has demonstrated blockbuster potential. |
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., December 31, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2024 (the "Grant Date") that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in December 2024. The equity awards were approved in accordance with Nasdaq Lis |
Sarepta Therapeutics, Inc. (SRPT): Is This Gene Therapy Stock a Good Buy Right Now?We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat […] |
Exploring High Growth Tech Stocks in the US December 2024The United States market has recently experienced a 2.8% increase over the past week and a substantial 24% climb over the last year, with earnings expected to grow by 15% per annum in the coming years. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to leverage these favorable market conditions. |
Is Sarepta Therapeutics, Inc. (SRPT) the Best Performing Biotech Stock in 2024?We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other biotech stocks. The Booming Biotechnology Sector The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, […] |
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and AlnylamSarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam are included in this Analyst Blog. |
4 Biotech Stocks Most Wall Street Analysts Are Bullish AboutHere, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals. |
Sarepta completes subject dosing in Phase III LGMD2E/R4 therapy trialData from the trial are expected in the first half of next year. |
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular DisorderThe phase III EMERGENE study evaluates Sarepta's experimental gene therapy for an ultra-rare form of muscle disorder for which there is no treatment beyond symptom management. |